Aktiviteter per år
Concerns have been raised regarding a potentially increased risk of cancer associated with treatment with glucagon-like peptide-1 (GLP-1) receptor agonists. Here, we explored whether fasting and oral glucose tolerance test post-challenge glucose-dependent insulinotropic peptide (GIP) and GLP-1 levels were associated with incident first cancer. Within the cardiovascular re-examination arm of the population-based Malmö Diet Cancer study (n = 3734), 685 participants with a previous cancer diagnosis were excluded, resulting in 3049 participants (mean age 72.2 ± 5.6 years, 59.5% women), of whom 485 were diagnosed with incident first cancer (median follow-up time 9.9 years). Multivariable Cox-regression and competing risk regression (death as competing risk) were used to explore associations between incretin levels and incident first cancer. Higher levels of fasting GLP-1 (462 incident first cancer cases/2417 controls) showed lower risk of incident first cancer in competing risk regression (sub-hazard ratio 0.90; 95% confidence interval 0.82–0.99; p = 0.022). No association was seen for fasting GIP, post-challenge GIP, or post-challenge GLP-1 and incident first cancer. In this prospective study, none of the fasting and post-challenge levels of GIP and GLP-1 were associated with higher risk of incident first cancer; by contrast, higher levels of fasting GLP-1 were associated with lower risk of incident first cancer.
|Status||Published - 2023 jan. 7|
- Cancer och onkologi
FingeravtryckUtforska forskningsämnen för ”Endogenous incretin levels and risk of first incident cancer: a prospective cohort study”. Tillsammans bildar de ett unikt fingeravtryck.
- 1 Handledning av forskarstuderande
Adrenomedullin in sepsis
Hans Friberg (Första/primär/huvudhandledare), Olle Melander (Andra handledare), Attila Frigyesi (Andra handledare) & Michelle Chew (Andra handledare)2017 sep. 25 → 2022 sep. 16
Aktivitet: Examination och handledarskap › Handledning av forskarstuderande